King Pharmaceuticals Inc. said Tuesday it completed its $1.6 billion purchase of rival Alpharma, unifying two pain drug makers.
Intervention of Prime Minister Manmohan Singh has been sought to form a high powered Parliamentary committee on the lines of Hathi Committee of 1978 to frame a comprehensive policy to help the small and medium scale pharma units so as to make India a hub of quality medicines at affordable prices in public interest.
Alarmed over the sweeping powers enjoyed by the drug control officers under the recently amended Drugs and Cosmetics Act, the IDMA has asked the government to clip the wings of these officers, including drug inspectors, by issuing written guidelines to be followed by them while initiating action against the drug companies. The IDMA also asked for an amendment to Rule 51 and 52 to make it mandatory to get written consent from the controlling authority for filing prosecution against the drug companies.
Dr. Reddy’s Laboratories Ltd. (NYSE:RDY) today announced the appointment of Mr Umang Vohra as the new CFO of the company. Umang was the Deputy CFO and his elevation has been part of the company’s leadership development and transition programme. He joined Dr. Reddy’s in 2002 from PepsiCo and has been part of several of the company’s key initiatives like Acquisitions, R&D de-risking transactions, and operational improvements in Accounting, Governance and Finance processes.
Matrix Laboratories, a Indian subsidiary of Mylan Inc., with controlling stake of 71.5 per cent, has received final approval from the US FDA for Stavudine capsules USP, 15 mg, 20 mg, 30 mg and 40 mg.
Watson Pharmaceuticals, Inc, a leader in generic and specialty branded pharmaceuticals, announced that its subsidiary, Watson Laboratories, Inc, has received final approval from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for desogestrel/ethinyl estradiol and ethinyl estradiol tablets USP, 0.15 mg / 0.02 mg. Desogestrel/ethinyl estradiol and ethinyl estradiol tablets, USP, is the generic equivalent to Duramed Pharmaceuticals' Mircette low-dose monthly oral contraceptive product, which is indicated for prevention of pregnancy.
Eurand NV, a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies, has been advised by GlaxoSmithKline (GSK) that the US Food and Drug Administration (FDA) has issued a Complete Response letter for the New Drug Application (NDA) for EUR-1048. EUR-1048 is an orally disintegrating tablet (ODT) formulation with an undisclosed active compound co-developed by Eurand and GSK.
Science Beyond Frontiers (SBF) Healthcare, a well-known provider of Rotational Field Quantum Magnetic Resonance (RFQMR) therapy to treat osteoarthritis and cancer patients is now looking to raise funds to the tune of $5 million for expansion of operations.
Claris Lifesciences, a global lifesciences company has received the 'Frost and Sullivan' Gold award for Manufacturing Excellence in Healthcare – Large Enterprise for 'Clarion'. Clarion is the state of the art manufacturing facility of Claris Lifesciences Ltd. This is the second consecutive year that Clarion has received this award.
Novo Nordisk and VLST Corporation, a Seattle-based biotechnology company focused on the development of therapeutics for autoimmune and inflammatory disorders, have entered into an exclusive, worldwide collaboration agreement to develop therapeutic targets utilising VLST's technology platform in the fields of autoimmune and inflammatory disorders.
Breckenridge has entered into another separate agreement with Helm AG to develop and manufacture an ANDA for an asthma drug product. Under terms of this new agreement, Breckenridge will submit an ANDA to the US Food and Drug Administration (FDA) in 2009 for the product which is in development by Helm AG. The product currently shows US sales of approximately $4 Billion Dollars, and is patent protected until 2012.
Intercell AG announced that the phase-II clinical trial with the company's vaccine candidate to prevent infections with the bacterium Pseudomonas aeruginosa is starting. Intercell's vaccine (IC43) is a recombinant subunit vaccine consisting of two outer membrane proteins of Pseudomonas aeruginosa.
Can-Fite BioPharma has achieved yet another goal by completion of enrolment of 230 patients in its confirmatory phase-IIb RA trial. Approximately 230 patients were enrolled to this study, randomized into three groups treated with 0.1 mg and 4 mg of CF101, and placebo. Patients are taking the drug for 12 weeks plus two weeks of follow-up. The trial is being conducted in 30 sites in Europe and Israel. The company estimate to release study data on H1 2009.
Array BioPharma Inc has received its second draw of $40 million from Deerfield Management, a leading healthcare investment organization and one of Array's largest shareholders. Deerfield committed $80 million to Array in May 2008 and provided the first $40 million draw to Array in June 2008. Together with existing capital, these funds are being use to advance Array's seven wholly-owned small molecule drug programmes in development.
SemBioSys Genetics Inc, announced that MannKind Corporation has purchased an option to license rights to SemBioSys' proprietary plant-produced recombinant human insulin. The option period ends on March 31, 2009. Terms of the option stipulate that the primary use of SemBioSys' plant-produced insulin would be for Afresa, MannKind's ultra-rapid acting insulin, which recently completed phase-3 studies.
Consequent upon the reduction in the rate of Excise duty on medicines from 8% to 4% notified by the Ministry of Finance, Department of Revenue, all manufacturers and marketing companies of formulations packs are advised to ensure that the benefit of this excise duty reduction and the reduced rate of abatement is passed on to the consumers through reduced Maximum Retail Price (MRP). The National Pharmaceutical Pricing Authority (NPPA) in India has asked the pharmaceutical companies to reduce the MRP.
Ireland-based Tibotec, which is the subsidiary of Johnson & Johnson, has signed a royalty-free, non-exclusive license agreement with India’s Emcure Pharmaceuticals to distribute the protease inhibitor darunavir (DRV) in India.
Plethico Pharmaceuticals of India has acquired a 20% stake in a retail pharmacy chain in the CIS from Tricon Holdings of Hong Kong for $20 million. Tricon deals in the pharmaceutical retail business with a sourcing base in the UAE.
The International Society for Stem Cell Research (ISSCR), the world's leading professional organization of stem cell researchers, released new guidelines for the responsible development of safe and effective stem cell therapies for patients.
Asuragen, Inc.’s Signature® LTx v2.0 Leukemia Translocation Panel was released as a "Conformité Européenne" or "European Conformity" CE IVD product under the European Directive on In Vitro Diagnostic Medical Devices.